Jennison Associates LLC Arcutis Biotherapeutics, Inc. Transaction History
Jennison Associates LLC
- $149 Billion
- Q1 2024
A detailed history of Jennison Associates LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Jennison Associates LLC holds 12,176,315 shares of ARQT stock, worth $117 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
12,176,315
Previous 9,066,082
34.31%
Holding current value
$117 Million
Previous $29.3 Million
312.07%
% of portfolio
0.08%
Previous 0.02%
Shares
8 transactions
Others Institutions Holding ARQT
# of Institutions
172Shares Held
126MCall Options Held
498KPut Options Held
1.64M-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$84.3 Million4.57% of portfolio
-
State Street Corp Boston, MA8.78MShares$84.3 Million0.0% of portfolio
-
Suvretta Capital Management, LLC New York, NY7.88MShares$75.6 Million3.34% of portfolio
-
Rubric Capital Management LP New York, NY7.51MShares$72.1 Million2.54% of portfolio
-
Polar Capital Holdings PLC London, X06.89MShares$66.1 Million0.43% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $578M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...